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Abstract
Background. In the diabetic kidney, stimulation of
mitogen-activated protein kinases (MAPKs) leads to ex-
tracellular matrix protein synthesis. In the proximal tubule,
angiotensin-(1–7)[Ang-(1–7)]blocksactivationofMAPKs
byangiotensinII.WestudiedtheeffectofAng-(1–7)onsig-
nalling responses in LLC-PK1 cells in normal (5 mM) or
high (25 mM) glucose.
Methods. The p38 MAPK was assayed by immunoblot,
Src homology 2-containing protein-tyrosine phosphatase-1
(SHP-1) activity was measured after immunoprecipitation,
cell protein synthesis was determined by [3H]-leucine in-
corporation and transforming growth factor-β1( T G F - β1),
fibronectin and collagen IV were assayed by immunoblots
and/or ELISA.
Results. High glucose stimulated p38 MAPK. This re-
sponse was inhibited by Ang-(1–7) in a concentration-
dependent fashion, an effect reversed by the receptor Mas
antagonist A-779. Ang-(1–7) increased SHP-1 activity, via
the receptor Mas. An inhibitor of tyrosine phosphatase,
phenylarsine oxide, reversed the inhibitory effect of Ang-
(1–7) on high glucose-stimulated p38 MAPK. Ang-(1–7)
inhibited high glucose-stimulated protein synthesis, and
blocked the stimulatory effect of glucose on TGF-β1. Con-
versely,Ang-(1–7)hadnoeffectonglucose-stimulatedsyn-
thesis of fibronectin or collagen IV.
Conclusions. These data indicate that in proximal tubular
cells, binding of Ang-(1–7) to the receptor Mas stimulates
SHP-1,associatedwiththeinhibitionofglucose-stimulated
p38 MAPK. Ang-(1–7) selectively inhibits glucose-
stimulated protein synthesis and TGF-β1. In diabetic
nephropathy, Ang-(1–7) may partly counteract the profi-
brotic effects of high glucose.
Keywords: angiotensin; diabetic nephropathy; proximal tubule; receptor
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Introduction
Diabetic nephropathy is a leading cause of end-stage renal
disease world-wide. The pathogenesis of this condition is
complex, but exposure of cells to high glucose activates a
varietyofsignallingpathways,includingmitogen-activated
proteinkinases(MAPKs),reactiveoxygenspeciesandpro-
duction of cytokines such as transforming growth factor-β1
(TGF-β1) and extracellular matrix proteins, which promote
progressive glomerulosclerosis and tubulointerstitial fibro-
sis [1].
The proximal tubule contains all components of the
renin–angiotensin system (RAS), and intratubular levels
of angiotensin II (Ang II) exceed circulating levels by 100-
to 1000-fold [2,3]. Diabetes stimulates intrarenal produc-
tion of Ang II, which causes progressive nephron injury,
as suggested in animal models and human studies that
have demonstrated the beneficial effects of angiotensin-
converting enzyme (ACE) inhibitors and AT1 receptor
blockers [4].
The discovery of angiotensin-converting enzyme 2
(ACE2) has added complexity to the role of the RAS in
diabetic nephropathy. ACE2 is a monocarboxypeptidase
that is not blocked by ACE inhibitors, and cleaves Ang
II to the heptapeptide fragment angiotensin-(1–7) [Ang-
(1–7)] [5,6]. ACE2 is highly expressed in the kidney, with
abundant levels in the proximal tubule, where it generates
Ang-(1–7) [7–9].Ang-(1–7) ispresentinthekidney atcon-
centrationscomparabletoAngII[10]andisassociatedwith
vasodilatation and modulation of sodium and water trans-
port [11–14]. Some of these effects occur via binding to the
Mas protein, identified as the receptor for Ang-(1–7) [15].
Information is limited on the signalling pathways associ-
ated with Ang-(1–7) in the kidney. However, in proximal
tubular cells Ang-(1–7) inhibits Ang II-stimulated MAPK
activation, via binding to the receptor Mas [16]. Ang-(1–7)
maytherebycounterbalancetheeffectsofAngII,andcould
serve a protective role in states of RAS activation, such as
diabetic nephropathy.
C   The Author [2009].
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In LLC-PK1 proximal tubular cells, high glucose acti-
vates MAPKs, which may be involved in the downstream
stimulation of responses associated with nephron injury
[17]. We therefore determined the effect of Ang-(1–7) on
high glucose-mediated signalling responses in LLC-PK1
cells. Our data reveal that Ang-(1–7) blocks high glucose-
stimulated p38 MAPK, an effect associated with activa-
tion of the Src-homology 2-containing protein-tyrosine
phosphatase-1 (SHP-1). Moreover, we show that Ang-(1–
7) inhibits high glucose-stimulated cell hypertrophy and
TGF-β1 production.
Materials and methods
Cell culture
TheLLC-PK1 cellline(AmericanTypeCultureCollection(ATCC),Man-
assas, VA, USA) was used for all studies. The cells were grown at 37◦C
in a humidified environment of 5% CO2 in Dulbecco’s modified Eagle’s
medium nutrient mixture-Ham’s F-12 (DMEM/F-12), supplemented with
10% fetal bovine serum (FBS), penicillin (100 U/ml) and streptomycin
(100 µg/ml). The cells were rendered quiescent 24 h prior to experi-
mentation by removal of serum, or, in cases where the experiments were
performed after 48–72 h, by reduction of FBS to 0.5%, to prevent cell
detachment.
Immunoblotting
Subconfluent LLC-PK1 cells were exposed to normal glucose (5 mM
D-glucose) or high glucose (25 mM D-glucose) in media various times,
with or without Ang-(1–7) (Bachem Bioscience Inc., King of Prussia, PA,
USA), or bradykinin (Sigma-Aldrich, St Louis, MO, USA) for 30 min,
followed by immunoblot assays for phosphorylated p38 MAPK. In all ex-
periments, L-glucose (20 mM) was added to the normal glucose media to
control for osmolality. In some experiments, the cells were preincubated
for 15–30 min with either the AT1 receptor antagonist losartan (10−6–
10−5 M, Merck Research Laboratories, Rahway, NJ, USA), the AT2 re-
ceptorantagonistPD123319(10−6–10−5 M,Sigma-Aldrich),thereceptor
Mas antagonist D-Ala7-Ang-(1–7) (A-779) (10−6–10−5 M, Bachem Bio-
science Inc.), the bradykinin B2 receptor antagonist HOE-140 (10−6 M)
(Sigma-Aldrich)ortheproteintyrosinephosphataseinhibitorphenylarsine
oxide (PAO) (10−7 M, Sigma-Aldrich) prior to incubation with Ang-(1–
7). Immunoblotting was performed as described [16]. Membranes were
incubated for 16 h at 4◦C with a 1:1000 dilution of anti-phosphospecific
antibodies to p38 MAPK (Cell Signaling Technology, New England Bi-
olabs Ltd, Pickering, Ontario, Canada). The p38 antibody recognizes the
α, β, γ and δ isoforms of p38. In some experiments, the primary antibody
was a rabbit polyclonal antibody to the receptor Mas (Abcam, Cambridge,
MA, USA). For fibronectin immunoblots, the membranes were incubated
for 16 h at 4◦C with a 1:2000 dilution of a rabbit anti-human fibronectin
antibody (Sigma-Aldrich).
To control for protein loading on phosphorylated p38 (pp38) MAPK
immunoblots, membranes were stripped and re-probed with antibodies to
total p38 MAPK (Cell Signaling Technology). Fibronectin immunoblots
from cell lysates were reprobed with antibody against β-actin (Sigma-
Aldrich), or by Ponceau staining for cell supernatants. Immunoblot sig-
nals were quantified by densitometry and corrected for total protein lev-
els, using an image-analysis software programme (Kodak Densitometer
1S440CF) [16].
Immunoprecipitation and protein tyrosine phosphatase assay
The activity of the protein tyrosine phosphatase SHP-1 was measured by
an immunoprecipitation assay, as described [18]. After 24 h in a serum-
free medium, LLC-PK1 cells were exposed to normal glucose (5 mM
D-glucose + 20 mM L-glucose) or high glucose (25 mM D-glucose) and
stimulated with Ang-(1–7) (10−7 M) for 30 min. In some experiments, the
cellswerepreincubatedfor15–30minwiththereceptorMasantagonistA-
779, or PAO (10−7 M) prior to incubation with Ang-(1–7). After washing
with PBS, the cells were lysed with immunoprecipitation buffer (15 mM
KCl, 10 mM HEPES (pH 7.6), 2 mM MgCl2, 0.1% NP40, 1 µg/ml apro-
tinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin A, 1 mM PMSF) for 10 min
on ice. After centrifugation at 10 000 × g for 5 min at room temperature,
cellsupernatantswereincubatedwithanantibodytoSHP-1(Transduction
Laboratories, Lexington, KY, USA) at 4◦C overnight followed by addition
of 30 µl Protein A-agarose beads (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and incubation for an additional 2 h at 4◦C. The beads were
washed and mixed with 100 µl of protein tyrosine phosphatase buffer (25
mMimidazole(pH7.2),45mMNaCl,1mMEDTA)containing30mMp-
nitrophenylphosphate(pNPP),followedbyincubationat37◦Cfor30min.
Therateofformationofp-nitrophenolfrompNPPwasdeterminedbyspec-
trophotometry at 410 nm. For each assay of protein tyrosine phosphatase
activity, the absorbance of pNPP hydrolyzed from beads containing con-
trol IgG (normal IgG) (Santa Cruz Biotechnology) alone was subtracted
from the absorbance of lysate immunoprecipitates. The absorbance for
the experimental groups was then normalized to the absorbance obtained
with control IgG immunoprecipitates. After measurement of protein ty-
rosine phosphatase activity, the beads were recovered and subjected to
SDS–PAGE for immunoblotting to detect the presence of SHP-1.
Collagen IV ELISA
After incubation of LLC-PK1 cells for 48–72 h in normal or high glu-
cose, collagen IV was measured in the cell culture supernatant, using a
commercial ELISA kit (Chemicon Int., Temecula, CA, USA).
TGF-β1E L I S A
The cells were incubated with agonists, and aliquots of the culture media
were collected. TGF-β1 was activated by treating the media with 1 N
HCl for 10 min at room temperature, followed by neutralization with 1.2
N NaOH/0.5 M HEPES. The levels of TGF-β1 were determined by a
quantitative sandwich enzyme immunoassay using a commercial TGF-β1
ELISA kit (R&D Systems, TWC Biosearch International, Hong Kong).
[3H]-Leucine incorporation
Afterreaching50–60%confluence,LLC-PK1 cellswereexposedtomedia
containing5mM D-glucoseor25mM D-glucose,supplementedwith0.5%
FBS, with or without Ang-(1–7) (10−7 M) or A-779 (10−5 M) for 48 h. To
measurecellproteinsynthesis,1µCiof L-[4,5-3H]-leucine(73.0Ci/mmol)
(Amersham, Mississauga, Ontario, Canada) was added to each well. After
16 h, the cells were washed four times in ice-cold PBS and lysed in 0.5 N
NaOHwith0.1%SDS.Thecell-associatedradioactivitywasmeasuredina
liquid scintillation counter. Leucine incorporation is reported as cpm/cell,
with cell counts determined with a haematocytometer.
Statistical analysis
Resultsarepresentedasmeans±SE.Forimmunoblots,controllaneswere
normalized to a value of unity as a reference, and the means ± SE are
presented for the other lanes. Significance, considered as P < 0.05, was
determined by one-way ANOVA with Bonferroni correction, in all cases
involving multiple comparisons.
Results
Effect of Ang-(1–7) on p38 MAPK phosphorylation
Initial experiments were performed to determine if LLC-
PK1 cellsexpresstheMasprotein,identifiedasthereceptor
for Ang-(1–7) [15]. Immunoblot assay in lysates of these
cellsrevealedasingleproteinbandof∼37kDa,confirming
the expression of the receptor Mas (data not shown).
Highconcentrationsofextracellularglucoseactivatep38
MAPK in LLC-PK1 cells [17]. Similarly, we found that ex-
posure of LLC-PK1 cells to media containing high glucose
(25 mM) increased p38 MAPK phosphorylation compared
to the cells in normal glucose (5 mM). In preliminary ex-
periments, this response peaked after 30 min incubation in
high glucose and persisted for 3–6 h. Preincubation of cells
withAng-(1–7)inhibitedthestimulatoryeffectofhighglu-
cose on p38 phosphorylation, in a concentration-dependent1768 E. Gava et al.
Fig. 1. Effect of Ang-(1–7) on high glucose-stimulated p38 MAPK phosphorylation. (A) Graph depicts the concentration-dependent inhibitory effect
of 30 min incubation with Ang-(1–7) (10−11–10−7 M) on high glucose (HG, 25 mM)-stimulated p38 MAPK phosphorylation in LLC-PK1 cells. NG,
normal glucose (5 mM). ∗P < 0.005 versus NG, ∗∗P < 0.05 versus NG, ∗∗∗P < 0.02 versus HG and P = NS versus NG; n = 10. (B) Graph depicts the
effect of normal glucose (NG, 5 mM) or high glucose (HG, 25 mM) for 30 min with or without Ang-(1–7) (10−7 M) or D-Ala7-Ang-(1–7) (A-779,
10−5 M), on p38 MAPK phosphorylation. Control cells were incubated in media supplemented with L-glucose (20 mM) to control for osmolality.
∗P < 0.001 versus NG and HG + Ang-(1–7), ∗∗P < 0.001 versus NG, and P < 0.05 versus HG + Ang-(1–7); n = 6–13. Results are presented as the
ratio of phosphorylated p38/total p38, in arbitrary units. Representative blots are depicted above the graphs, showing phosphorylated p38 (pp38) and
total p38 (p38).
fashion, with a maximal effect at 10−7 M (Figure 1A).
Furthermore, incubation of cells with A-779 (10−5 M) re-
versed the inhibitory effect of Ang-(1–7) on high glucose-
stimulated p38 MAPK phosphorylation, suggesting that
the effect of Ang-(1–7) is mediated via the receptor Mas
(Figure 1B).
In normal glucose (5 mM), incubation of cells with Ang-
(1–7) caused small concentration-dependent activation of
p38 MAPK, with a peak effect at 10−7 M (Figure 2A).
Pretreatment with A-779 (10−5 M), the AT1 receptor an-
tagonist losartan (10−6 M), or the AT2 receptor antago-
nist PD123319 (10−6 M) did not reverse this activation
(Figure 2B). In contrast, the bradykinin B2 receptor an-
tagonist HOE-140 (10−6 M) partly inhibited the Ang-(1–
7)-stimulated p38 MAPK phosphorylation in normal glu-
cose. Bradykinin also stimulated p38 MAPK phosphoryla-
tion in normal glucose, and this was reversed by HOE-140
(Figure 2C).
Effect of Ang-(1–7) on SHP-1 activity
Further experiments focused on a possible mechanism
for the inhibitory effect of Ang-(1–7) on high glucose-
stimulated p38 MAPK. In this regard, the effects of MAPK
signalling pathways may be regulated by the opposing
actions of tyrosine kinases and tyrosine phosphatases. Re-
cruitment of the protein tyrosine phosphatase SHP-1 to
its targets may suppress downstream signalling events [19,
20]. In cells incubated under either normal (5 mM) or high
glucose (25mM) conditions for 30 min, co-incubation with
Ang-(1–7) (10−7 M) significantly increased SHP-1 activ-
ity (Figure 3). No change in protein expression of SHP-1
was detected by immunoblot at this time point (not shown).
Activation of SHP-1 by Ang-(1–7) was significantly inhib-
ited when the cells were pretreated with A-779 (10−5 M)
(Figure 3).
Inhibition of tyrosine phosphatase blocks the inhibitory
effect of Ang-(1–7) on high glucose-stimulated p38 MAPK
To determine the role of Ang-(1–7)-stimulated SHP-1 ac-
tivation in mediating the inhibition of p38 phosphory-
lation in high glucose, the cells were preincubated for
15 min with the inhibitor of phosphotyrosine phosphatase
PAO [21]. PAO completely inhibited activation of SHP-1
activity under both normal and high glucose conditions
(Figure 4), and it also reversed the inhibitory effect of
Ang-(1–7)onhighglucose-stimulatedp38phosphorylation
(Figure 5).
Effect of Ang-(1–7) on cell protein synthesis
To determine the functional impact of the inhibitory ef-
fect of Ang-(1–7) on high glucose-stimulated p38 MAPK,
we examined the effects on cell protein synthesis, mea-
s u r e db y[ 3H]-leucine incorporation. Incubation of cells
for 48 h in high glucose caused a significant stimulation of
leucineincorporation,comparedtonormalglucose,andthis
was blocked by 48 h incubation with Ang-(1–7) (10−7 M)
(Figure 6). The inhibitory effect of Ang-(1–7) was com-
pletely prevented by co-incubation with A-779 (10−5 M).
Effect of Ang-(1–7) on TGF-β1, fibronectin and
collagen IV
Diabetic nephropathy is associated with high glucose-
induced synthesis of intrarenal TGF-β1, and extracellu-Ang-(1–7) activates SHP-1 in tubular cells 1769
Fig. 2. Effect of Ang-(1–7) on p38 MAPK phosphorylation in normal glucose. (A) Graph depicts the concentration-dependent stimulatory effect of
incubation of Ang-(1–7) (10−11–10−7 M) on phosphorylation of p38 MAPK in normal glucose (NG, 5 mM). By ANOVA, the effect of Ang-(1–7)
(10−7 M) was not significant compared to NG alone in this series of experiments;n = 7–8. Results are presented as the ratio of phosphorylated p38/total
p38, in arbitrary units. Representative blot is depicted above the graph, showing phosphorylated p38 (pp38) and total p38 (p38). (B) Graph depicts the
effect of Ang-(1–7) (10−7 M) in normal glucose (NG, 5 mM) with or without A-779 (10−5 M), Losartan (Los, 10−6 M) or PD123319 (PD, 10−6 M).
∗P < 0.05 versus control; n = 5–6. To control for the possible effects of osmolality in these experiments, incubations in NG were supplemented with
L-glucose (20 mM). Representative blot is depicted above the graph, showing phosphorylated p38 (pp38) and total p38 (p38). (C) Graph depicts the
effect of Ang-(1–7) (10−7 M) and bradykinin (BK) (10−7 M) in normal glucose (NG, 5 mM) with or without the B2 receptor antagonist HOE-140
(HOE, 10−6 M). ∗P < 0.05 versus control, ∗∗P < 0.001 versus control ∗∗∗P < 0.01 versus BK; n = 7–16. Representative blot is depicted above the
graph, showing phosphorylated p38 (pp38) and total p38 (p38).
lar matrix proteins [1]. Incubation of LLC-PK1 cells in
high glucose for 72 h caused a small but significant stim-
ulation of TGF-β1 production (Figure 7). This effect was
partly inhibited by Ang-(1–7) (10−7 M), in a receptor Mas-
dependent manner. In contrast, Ang-(1–7) had no signif-
icant effect on high glucose-stimulated production of fi-
bronectin, either cell-associated or secreted into the media
(Figure 8), and did not inhibit high glucose-stimulated syn-
thesis of collagen IV (Figure 9). In normal glucose, Ang-
(1–7) had no significant effect on TGF-β1, fibronectin or
collagen IV (Figures 7–9).
Discussion
There are several major findings in the current study that
are relevant to diabetic tubulointerstitial injury. First, in
proximal tubular cells, high glucose-stimulated activation
of p38 MAPK is blocked by Ang-(1–7) via binding to the
receptor Mas. Second, Ang-(1–7) activates the protein ty-
rosine phosphatase SHP-1, which may mediate the inhi-
bition of p38 MAPK phosphorylation. Third, Ang-(1–7)
inhibits high glucose-stimulated cell protein synthesis, and
blocks TGF-β1 production, but has no effect on production
of the matrix proteins fibronectin or collagen IV. Finally,
in normal glucose, Ang-(1–7) causes a small but signifi-
cant stimulation of p38 MAPK, which is mediated not by
the receptor Mas, but at least partly by a bradykinin B2
receptor-dependent pathway.
Treatment of streptozotocin (STZ)-diabetic rats with
Ang-(1–7) has recently been shown to diminish protein-
uria, and prevent abnormal vascular responsiveness [11],
suggesting that activation of Ang-(1–7) signalling could
represent a therapeutic strategy in diabetic nephropathy.1770 E. Gava et al.
Fig.3. EffectofAng-(1–7)onSHP-1activity.(A)Graphdepictstheeffect
of Ang-(1–7) (10−7 M) on SHP-1 activity in normal glucose (NG, 5 mM),
withorwithoutAng-(1–7)(10−7 M)orA-779(10−5 M). ∗P<0.05versus
control, ∗∗P < 0.05 versus Ang-(1–7); n = 3. (B) SHP- 1 activity in high
glucose (HG, 25 mM) is depicted with or without Ang-(1–7) (10−7 M) or
A-779 (10−5 M). ∗P < 0.01 versus control; ∗∗P < 0.01 versus Ang-(1–7);
n = 5. Results are presented in arbitrary units.
Strategies to inhibit high glucose-stimulated MAPK acti-
vation and subsequent downstream signalling in the prox-
imal tubule could be important in reducing tubulointer-
stitial injury. We observed that Ang-(1–7) inhibited high
glucose-stimulated p38 MAPK phosphorylation, and this
was reversed by administration of A-779, suggesting an ef-
fect mediated by binding of Ang-(1–7) to the receptor Mas.
MasisaGprotein-coupled cellsurfacereceptor (GPCR)of
325 amino acids, belonging to the Class A orphan GPCRs,
which contains approximately 50 receptors related to Mas
[22]. However, the intracellular signalling pathways asso-
ciated with binding of Ang-(1–7) to Mas have been incom-
pletely characterized. In NIH 3T3 cells, Mas stimulates
the GTP-binding protein Rac1, associated with activation
of p38 and c-jun N-terminal kinase (JNK) [23]. In a rat
heart in vivo and in human endothelial cells, Ang-(1–7)
stimulates Akt phosphorylation through Mas, which could
contribute positively to the cardiac actions of insulin and to
nitricoxiderelease,respectively[24,25].Ontheotherhand,
in cardiac myocytes, Ang-(1–7) inhibits MAPK activation
through the receptor Mas [26]. Studies in human endothe-
lial cells indicate that Ang-(1–7) negatively regulates Ang
II signalling by enhancing the association of c-Src with the
Src homology 2-containing inositol phosphatase 2 (SHP-
Fig. 4. Effect of phenylarsine oxide (PAO) on SHP-1 activity in normal
glucose or high glucose. (A) The effect of Ang-(1–7) (10−7 M) on SHP-1
activity in normal glucose is depicted (NG, 5 mM) with or without PAO
(10−7 M). ∗P < 0.001 versus control, ∗∗P < 0.001 versus Ang-(1–7);
n = 3. (B) The effect of Ang-(1–7) (10−7 M) on SHP-1 activity in high
glucose is depicted (HG, 25 mM) with or without PAO (10−7 M). ∗P <
0.01 versus control, ∗∗P < 0.05 versus Ang-(1–7); n = 5. Results are
presented in arbitrary units.
2), and by blocking the reduced phosphorylation of SHP-2
induced by Ang II [27].
Signalling associated with Ang-(1–7) in the proximal
tubule is poorly understood. Ang-(1–7) activates phospho-
lipase A2 in proximal tubular cells, associated with the
inhibition of sodium flux [28]. In an adult pig proximal
tubule, Ang-(1–7) blocks the stimulatory effect of Ang II
on Na+-ATPase activity, an effect prevented by a recep-
tor Mas antagonist [29]. Ang-(1–7) may also bind to Ang
II AT1 receptors in the proximal tubule, associated with
stimulation of phospholipase C-beta, protein kinase C and
activation of Na+-ATPase [30].
The current studies, along with our previous demonstra-
tion that Ang-(1–7) completely inhibits Ang II-stimulated
phosphorylation of the MAPKs p38, ERK and JNK [16],
suggested that Ang-(1–7) signalling might involve activa-
tion of a tyrosine phosphatase in the proximal tubule. We
investigated SHP-1 as a candidate tyrosine phosphatase,
since SHP-1 is activated by proximal tubular AT2 recep-
tors cloned from a variety of species [31]. SHP-1 is a
protein tyrosine phosphatase first described in the cyto-
plasmofhematopoieticcells,andmayfunctionasanegativeAng-(1–7) activates SHP-1 in tubular cells 1771
Fig. 5. PAO blocks the inhibitory effect of Ang-(1–7) on HG-stimulated
p38 MAPK. Graph depicts the effect of Ang-(1–7) (10−7 M) on high
glucose(HG,25mM)-stimulatedp38MAPKwithorwithoutphenylarsine
oxide (PAO, 10−7 M). ∗P < 0.05 versus control; n = 7. Results are
presented as the ratio of phosphorylated p38/total p38, in arbitrary units.
Representative blot is depicted above the graph, showing phosphorylated
p38 (pp38) and total p38 (p38).
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Fig. 6. Ang-(1–7) inhibits high glucose-stimulated cell protein synthesis.
Graph depicts the effect of Ang-(1–7) (10−7 M) in normal glucose (NG,
5 mM) and high glucose (HG, 25 mM) for 48 h, with or without A-779
(10−5 M) on cell protein synthesis, measured by [3H]-leucine incorpo-
ration. ∗P < 0.001 versus NG control, ∗∗P < 0.001 versus A-779 +
Ang-(1–7), P < 0.010 versus HG control, and P < 0.030 versus HG +
A-779; n = 5–11.
regulator of intracellular signal transduction [32]. In vascu-
lar smooth muscle cells, the Ang II AT2 receptor-mediated
inhibition of JNK activation and c-Jun expression, and in-
hibition of ERK phosphorylation, involves activation of
SHP-1 [19,20]. The current studies indicate for the first
time that significant increases in SHP-1 activity are in-
duced by Ang-(1–7) in proximal tubular cells, and this is
inhibited by the receptor Mas antagonist A-779. Further-
more, SHP-1 activation by Ang-(1–7) was blocked by the
tyrosinephosphataseantagonistPAO,andPAOreversedthe
inhibitory effect of Ang-(1–7) on p38 MAPK phosphoryla-
tion. Although our data are consistent with the hypothesis
that Ang-(1–7)-stimulated SHP-1 mediates the inhibition
of p38 MAPK phosphorylation in high glucose, PAO is a
non-specific inhibitor of tyrosine phosphatases, and there-
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Fig. 7. Effect of Ang-(1–7) on high glucose-stimulated TGF-β1. Graph
depicts the effect of Ang-(1–7) (10−7 M) on TGF-β1 in normal glucose
(NG, 5 mM) and high glucose (HG, 25 mM) for 72 h, with or without
A-779 (10−5 M). TGF-β1 synthesis was measured by ELISA. ∗P < 0.05
versus NG control; n = 5.
fore, other tyrosine phosphatases or even dual-specificity
phosphatases (DUSPs) could be involved in the regulation
ofMAPKsignallingbyAng-(1–7)inproximaltubularcells.
Thus,inLLC-PK1 cells,atrialnatriureticpeptidestimulates
expression of the DUSP MKP-1, a phosphatase involved in
dephosphorylation of ERK [33], while in human embry-
onic 293T cells, coordinated activation of multiple DUSPs
causes dephosphorylation of JNK [34].
High glucose stimulates proximal tubular cell hypertro-
phy,TGF-βproductionandsynthesisofextracellularmatrix
proteins such as fibronectin and collagen IV, which con-
tribute to tubulointerstitial fibrosis in diabetic nephropa-
thy [17,35–37]. Ang-(1–7) inhibited cell protein synthe-
sis induced by high glucose, as well as glucose-stimulated
TGF-β1 production, through binding to the receptor Mas.
However, we observed no significant inhibitory effect of
Ang-(1–7) on the levels of fibronectin or collagen IV in-
duced by high glucose. These data suggest that other pro-
teins associated with cell hypertrophy are affected by Ang-
(1–7) in the proximal tubule, and that TGF-β1 synthesis is
not necessary for fibronectin or collagen IV production in
these cells. Moreover, the role of SHP-1 activation in medi-
atingtheinhibitoryeffectofAng-(1–7)onglucose-induced
cell hypertrophy and TGFβ-1 production remains unclear.
Use of PAO for 48–72 h was associated with cell toxicity
in our studies, and other strategies (e.g. siRNA) will be
necessary to address this question.
In a normal glucose medium, Ang-(1–7) caused a small
but significant stimulation of p38 MAPK phosphorylation,
whichwasnotinhibitedbythereceptorMasantagonist,nor
by AT1 or AT2 receptor blockers. Similarly, we observed a
non-significant stimulation of [3H]-leucine incorporation
by Ang-(1–7) in normal glucose (Figure 6). In previous
studies in rat proximal tubular cells, we observed that Ang-
(1–7) alone caused a 19% increase in p38 MAPK phos-
phorylation, although this did not achieve statistical signif-
icance [16]. In the present studies, the bradykinin B2 re-
ceptor antagonist HOE-140 inhibited the small stimulatory
effectofAng-(1–7)onp38MAPK,suggestingthatAng-(1–
7)caninteractwithbradykininsignallinginthesecells.The
mechanism underlying this interaction remains obscure.
In other tissues, complex interactions between Ang-(1–7)1772 E. Gava et al.
Fig. 8. Effect of Ang-(1–7) on fibronectin production. Graphs depict effects of Ang-(1–7) (10−7 M) on high glucose-stimulated production of
fibronectin, either cell-associated (A) or secreted into the media (B), in the presence or absence of A-779 (10−5 M). Sample immunoblots for
fibronectin are shown above, with β-actin blot below in (A) and Ponceau staining of proteins below in (B). ∗P < 0.05 versus NG, ∗∗P < 0.01 versus
NG; n = 4.
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Fig. 9. Effect of Ang-(1–7) on collagen IV production. Graph depicts
the effect of Ang-(1–7) (10−7 M) on collagen IV production in normal
glucose (NG, 5 mM) and high glucose (HG, 25 mM) for 72 h, with or
without A-779 (10−5 M). Collagen IV synthesis was measured by ELISA.
∗P < 0.001 versus NG control, ∗∗P < 0.05 versus NG control, ∗∗∗P <
0.01 versus NG control; n = 7.
and bradykinin B2 receptor responses have been described.
Endogenous Ang-(1–7) potentiates the bradykinin-induced
vasodepressor effect induced by ACE inhibition [38], and
thisappearstoinvolveadirectinteractionbetweenAng-(1–
7) and a B2 receptor pathway, without requirement for the
receptorMas[39].Takentogether,ourdataalsosuggestthat
under normal glucose conditions, Ang-(1–7) may activate
a B2 receptor-dependent signalling pathway in LLC-PK1
cells, which is linked to p38 MAPK activation and down-
stream increases in protein synthesis. However, since we
observed only a partial inhibitory effect of HOE-140 on the
response to Ang-(1–7) in normal glucose, other pathways
may be involved, also independent of the receptor Mas.
In summary, Ang-(1–7) activates SHP-1 in proximal
tubular cells, and inhibits glucose-stimulated p38 MAPK,
cell protein synthesis and TGF-β1 production, with no ef-
fect on the matrix proteins fibronectin or collagen IV. The
results suggest that in the diabetic kidney, Ang-(1–7) may
partlyprotectagainsttheprofibroticeffectsofhighglucose.
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